BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Clinical Trials

CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China

Pre-clinical trial results showed that CanSinoBIO's COVID-19 mRNA vaccine can induce high-titer neutralizing antibody levels against multiple SARS-CoV-2 va...

April 04, 2022 | News

JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in Mantle Cell Lymphoma in China

Carteyva® is an anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product independently developed by JW Therapeutics. T...

April 04, 2022 | News

eTheRNA Manufacturing Announces New LNP Formulation Development and Production Service

This new LNP service uses eTheRNA’s proprietary lipid libraries and proprietary formulations to facilitate targeted delivery and tailored biodistribu...

March 29, 2022 | News

Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue Tablets to the Philippines

Daewoong Pharmaceutical (CEO Sengho Jeon & Changjae Lee) recently announced that it has submitted the New Drug Application (NDA) for a n...

March 29, 2022 | News

Henlius Receives NMPA Approval for its First Innovative Monoclonal Antibody HANSIZHUANG

Furthermore, it also empowers the domestic precision immunotherapy for tumors and promotes the high-quality development of China's biopharmaceuti...

March 28, 2022 | News

Innovent and Lilly Expand Strategic Partnership in Oncology

i) an agreement for Innovent to obtain the sole commercialization rights to import, market, promote, distribute and detail Cyramza® (ramucirumab) ...

March 28, 2022 | News

Aquavit Files IND with FDA for DTX-021, a New Botulinum Toxin

DTX-021 is a botulinum toxin type A drug intended for the treatment of moderate to severe glabellar lines. DTX-021 is a highly purified and clinically test...

March 25, 2022 | News

New clinical trial collaboration for Cu-64 SAR-bisPSMA in prostate cancer

The X-Cancer's investigator-led trial of SAR-bisPSMA in known or suspected prostate cancer (X-Calibur) is a Phase I/II IIT in up to 150 patients at the Uro...

March 25, 2022 | News

RNAGENE Signs a Collaborative Research Agreement with PharmAbcine to Develop Novel mRNA Therapeutics

Under the agreement, both companies will collaborate to develop next-generation mRNA-based antibody therapeutics by utilizing the proprietary mRNA platform...

March 22, 2022 | News

BioVaxys Announces Bioproduction of BVX-1021

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), today announced that it has entered into an agreem...

March 21, 2022 | News

Lynk Pharmaceuticals and Simcere announced Strategic Commercialization Partnership

Under the terms of the agreement, Lynk Pharmaceuticals is responsible for the development of the product. Simcere will obtain the exclusive rights to marke...

March 18, 2022 | News

Everest Medicines to further enhance its international commercial footprint

Everest Medicines , a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical u...

March 14, 2022 | News

Suvoda Unveils New Brand to Reflect Expanded Focus in Complex Clinical Trial Management

Suvoda LLC today launched a refreshed brand, to better reflect its leadership position as a global clinical trial technology company that specia...

March 09, 2022 | News

Veristat Expands its Expertise and Scale across Biopharma and Medtech

Veristat, a scientific-minded global clinical research organization (CRO), announced today the expansion and strengthening of its service capabilities by a...

March 08, 2022 | News

Stay Connected